Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 3, 2005 - Issue 4
Submit an article Journal homepage
32
Views
2
CrossRef citations to date
0
Altmetric
Review

Hypertension 2005: an evidence-based approach to diagnosis and treatment – an American perspective

Robert A Phillips New York University School of Medicine, Department of Medicine, Lenox Hill Hospital, New York, NY 10021, USA. [email protected]
&
Joy M Weinberg Department of Medicine, Lenox Hill Hospital, New York, NY 10021, USA. [email protected]
Pages 691-704 | Published online: 10 Jan 2014

References

  • Veterans AdministrationCooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity in hypertension: results in patients with diastolic blood pressures averaging 115 through 129 mm Hg. JAMA 202, 1028–1034 (1967).
  • Joint National Committee.Report of the Joint National Committee on Detection, Evaluation, andTreatment of High Blood Pressure. A cooperative study. JAMA 237, 255–261 (1977).
  • Phillips RA, Diamond JA. Ambulatory blood pressure monitoring and echocardiography – noninvasive techniques for evaluation of the hypertensive patient. Prog. Cardiovasc. Dis.41(6), 397–440 (1999).
  • O'Brien E, Asmar R, Beilin L et al. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J. Hypertens.23(4), 697–701 (2005).
  • Hinman A, Engel BT, Bickford AF. Portable blood pressure recorder. Accuracy and preliminary use in evaluating intradaily variations. Am. Heart J. 63, 663 (1962).
  • O'Brien E, Atkins N, Staessen J. Factors influencing validation of ambulatory blood pressure measuring devices. J. Hypertens.13(11), 1235–1240 (1995).
  • Pickering TG, James GD, Boddie C, Harshfield GA, Blank S, Laragh JH. How common is white coat hypertension? JAMA 259, 225–228 (1988).
  • Eison H, Phillips RA, Ardeljan M, Krakoff LR. Differences in ambulatory blood pressure between men and women with mild hypertension. J. Hum. Hypertens. 4, 400–404 (1990).
  • Staessen JA, O'Brien ET, Atkins N, Amery AK. Short report: ambulatory blood pressure in normotensive compared with hypertensive subjects. The Ad-Hoc Working Group. J. Hypertens.11(11), 1289–1297 (1993).
  • Martin KL, Phillips RA, Krakoff LR. Persistent white coat hypertension. Am. J. Hypertens. 7, 368–370 (1994).
  • Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien ET, Fagard R. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. JAMA 278, 1065–1072 (1997).
  • Kuwajima I, Suzuki Y, Fujisawa A, Kuramoto K. Is white coat hypertension innocent? Structure and function of the heart in the elderly. Hypertension22(6), 826–831 (1993).
  • Verdecchia P, Porcellati C, Schillaci G et al. Ambulatory blood pressure: an independent predictor of prognosis in essential hypertension. Hypertension24(6), 793–801 (1994).
  • Celis H, Fagard RH. White-coat hypertension: a clinical review. Eur. J. Inter. Med.15(6), 348–357 (2004).
  • Clement DL, De Buyzere ML, De Bacquer DA et al. Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N. Engl. J. Med.348(24), 2407–2415 (2003).
  • Lurbe E. Increase in nocturnal blood pressure and progression to microalbuminuria in type 1 diabetes. N. Engl. J. Med. 347, 797–805 (2002).
  • Fagard RH, Staessen JA, Thijs L et al. Response to antihypertensive therapy in older patients with sustained and nonsustained systolic hypertension. Circulation102(10), 1139–1144 (2000).
  • Bobrie G, Chatellier G, Genes N et al. Cardiovascular prognosis of ‘masked hypertension’ detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA291(11), 1342–1349 (2004).
  • Bjorklund K, Lind L, Zethelius B, Andren B, Lithell H. Isolated ambulatory hypertension predicts cardiovascular morbidity in elderly men. Circulation107(9), 1297–1302 (2003).
  • ALLHAT Investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288(23), 2981–2997 (2002).
  • Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA289(19), 2560–2571 (2003).
  • Turnbull F. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet362(9395), 1527–1535 (2003).
  • Julius S, Kjeldsen SE, Weber MA et al. Outcomes in hypertensive pateints at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the value randomized trial. Lancet 363, 2022–2031 (2004).
  • Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in pateints with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 292, 2217–2226 (2004).
  • Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J. Hypertens. 21, 1055–1076 (2003).
  • Neaton JD, Grimm RH Jr, Prineas RJ et al. Treatment of mild hypertension study: final results. JAMA 270, 713–724 (1993).
  • Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int.61(3), 1086–1097 (2002).
  • Brown MJ, Palmer CR, Castaigne A et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International nifedipine-GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet356(9227), 366–372 (2000).
  • Hansson L, Hedner T, Lund-Johansen P et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet356(9227), 359–365 (2000).
  • Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet359(9311), 995–1003 (2002).
  • Julius S, Alderman MH, Beevers G et al. Cardiovascular risk reduction in hypertensive black patients with left ventricular hypertrophy: the LIFE study. J. Am. Coll. Cardiol.43(6), 1047–1055 (2004).
  • UK Prospective DiabetesStudy Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 317, 713–720 (1998).
  • Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342(3), 145–153 (2000).
  • Hansson L, Lindholm LH, Ekbom T et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet354(9192), 1751–1756 (1999).
  • Wing LMH, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med.348(7), 583–592 (2003).
  • Wassertheil-Smoller S, Psaty BM, Greenland P et al. Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 292, 2849–2859 (2004).
  • Pepine CJ, Handberg EM, Cooper-DeHoff RM et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA290(21), 2805–2816 (2003).
  • Wright JT Jr, Agodoa L, Contreras G et al. Successful blood pressure control in the African–American Study of Kidney Disease and Hypertension. Arch. Intern. Med.162(14), 1636–1643 (2002).
  • Kjeldsen SE, Dahlof B, Devereux RB et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA288(12), 1491–1498 (2002).
  • Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med.115(1), 41–46 (2003).
  • Gottdiener JS, Reda DJ, Massie BM, Materson BJ, Williams DW, Anderson RJ. Effect of single-drug therapy on reduction of left ventricular mass in mild to moderate hypertension: comparison of six antihypertensive agents. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Circulation95(8), 2007–2014 (1997).
  • PROGRESS Collaborative Group. Randomized trial of a perindopirl-based blood-pressure-lowering regimen among 6105 individuals with previous storke or transient ischemic attack. Lancet 358, 1033–1041 (2001).
  • Amery A, Birkenhager W, Brixko P et al. Glucose intolerance during diuretic therapy in elderly hypertensive patients. A second report from the European Working Party on High blood pressure in the Elderly (EWPHE). Postgrad. Med. J.62(732), 919–924 (1986).
  • Kostis JB, Wilson AC, Freudenberger RS, Cosgrove NM, Pressel SL, Davis BR. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am. J. Cardiol.95(1), 29–35 (2005).
  • Curb JD, Pressel SL, Cutler JA et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA 276(23), 1886–1892 (1996).
  • Verdecchia P, Reboldi G, Angeli F et al. Adverse prognostic significance of new diabetes in treated hypertensive subjects. Hypertension43(5), 963–969 (2004).
  • Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351(9118), 1755–1762 (1998).
  • Estacio RO, Jeffers BF, Gifford N, Schrier RW. Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes. Diabetes Care B54-B64 (2004).
  • Klahr S, Levey AS, Beck GJ et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. The Modification of Diet in Renal Disease Study Group. N. Engl. J. Med. 330(13), 877–884 (1994).
  • Wright JT Jr, Bakris G, Greene T et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA288(19), 2421–2431 (2002).
  • Bakris GL, Williams M, Dworkin L et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am. J. Kidney Dis.36(3), 646–661 (2000).
  • Benet LZ, Sheirner LB. Design and optimization of dosage regimens: pharmacokinetic data. In: The Phamacological Basis of Therapeutics. Goodman AG, Gillman LS, Rall TW, Murad F (Eds), MacMillan Publishing Company, NY, USA, 1663–1733 (1985).
  • Gueyffier F, Bulpitt C, Boissel JP et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. Lancet353(9155), 793–796 (1999).
  • SHEP Cooperative ResearchGroup. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 265, 3255–3264 (1991).
  • Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension). Lancet 338, 1281–1285 (1991).
  • Bulpitt CJ, Beckett NS, Cooke J et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J. Hypertens.21(12), 2409–2417 (2003).
  • Lever AF, Ramsay LE. Treatment of hypertension in the elderly. J. Hypertens. 13, 571–579 (1995).
  • Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch. Intern. Med.162(18), 2046–2052 (2002).
  • Perry HMJ, Davis BR, Price TR et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA284(4), 465–471 (2000).
  • Somes GW, Pahor M, Shorr RI, Cushman WC, Applegate WB. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch. Intern. Med.159(17), 2004–2009 (1999).
  • Smulyan H, Safar M. The diastolic blood pressure in systolic hypertension. Ann. Intern. Med.132(3), 233–237 (2000).
  • Braunwald E, Domanski MJ, Fowler SE et al. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med. 351(20), 2058–2068 (2004).
  • Poole-Wilson PA, Lubsen J, Kirwan BA et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet364(9437), 849–857.

Websites

  • Claims Processing Instructions for Ambulatory Blood Pressure Monitoring www.cms.hhs.gov/medlearn/matters/ mmarticles/2004/MM2726.pdf (Accessed June 2005)
  • Action to Control Cardiovascular Risk in Diabetes (ACCORD) www.clinicaltrials.gov/ct/show/ NCT00000620?order=7 (Accessed June 2005)
  • The DASH Eating Plan www.nhlbi.nih.gov/health/public/heart/hbp/dash/new_dash.pdf (Accessed June 2005)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.